Utility of PharmacoGenomics for Reducing Adverse Drug Effects

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Study of BHV-4157 in Alzheimer's Disease

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Escitalopram for Agitation in Alzheimer's Disease

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

A Study of RO7105705 in Patients With Moderate Alzheimer's Disease

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

A Study of LY3154207 in Participants With Parkinson's Disease Dementia

A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy